Skip to main content

Table 1 Baseline characteristics of the patients and laboratory tests

From: Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study

Variables

PAs-HSOS

BCS

P

Erythrocytes, 1012/L

5.00 ± 4.33

4.33 ± 0.84

0.053

Hemoglobin, g/L

135.99 ± 26.81

128.11 ± 24.00

0.061

Leukocyte, 109/L

6.90 ± 2.81

4.87 ± 2.59

<0.001

Platelet, 109/L

114.06 ± 63.48

119.37 ± 83.98

0.651

ALT, U/L

134.5 ± 154.89

40.60 ± 64.75

0.002

AST, U/L

146.31 ± 156.30

49.72 ± 54.81

0.001

ALP, U/L

170 ± 106.89

122.25 ± 69.08

0.003

γ-GT, U/L

160.52 ± 114.56

106.60 ± 85.94

0.002

T-BIL, μmol/L

65.07 ± 78.83

35.58 ± 28.47

0.001

Albumin, g/L

30.71 ± 5.50

35.51 ± 6.29

<0.001

PT, S

17.43 ± 2.64

15.63 ± 2.01

<0.001

Urea, mmol/L

7.19 ± 3.63

5.26 ± 2.76

0.001

Cr, μmol/L

90.65 ± 45.61

64.16 ± 18.67

<0.001

  1. Note: Baseline characteristics of PAs-induced HSOS refer to initial examination during first visit to our hospitals. PAs-HSOS PAs-induced HSOS; BCS Budd-Chiari syndrome; normal ranges: erythrocytes: 3.0–5.5 × 1012/L; hemoglobin: 110–160 g/L; leukocyte: 4–10 × 109 /L; platelet: 100–300 × 109/L; alanine aminotransferase: 5–35 U/L; aspartate aminotransferase (AST):8-40 U/L; alkaline phosphatase (ALP) 40–150 U/L; total bilirubin (T-BIL): 5.1–19 μmol/L; γ-glutamyl transpeptidase (γ-GT) 7–32 U/L; albumin: 35-55 g/L; prothrombin time (PT): 11–16 S; urea: 3.2–7.1 mmol/L; creatinine (Cr): 44–106 μmol/L.